Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 16.54% is 103% above its 5-year average of -585.77%, near the high end of its 5-year range (-6161.27%–17.33%).
100.80% above its 12-month average of -2068.98%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2026-03-31): -56.95%.
GROSS MARGIN
16.54%
GROSS MARGIN AVG TTM
-2068.98%
GROSS MARGIN AVG 3Y
-924.37%
GROSS MARGIN AVG 5Y
-585.77%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.80%
CURRENT VS 3Y AVG
+101.79%
CURRENT VS 5Y AVG
+102.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-59.86%
vs the sector median at left
Paranovus Entertainment Technology Ltd.
Market Cap
$3.28M
Gross Margin
16.54%
TTM Avg
-2068.98%
3Y Avg
-924.37%
5Y Avg
-585.77%
Market Cap
$3.30M
Gross Margin
79.65%
TTM Avg
78.98%
3Y Avg
76.82%
5Y Avg
80.07%
Market Cap
$3.21M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$3.14M
Gross Margin
92.09%
TTM Avg
93.19%
3Y Avg
96.59%
5Y Avg
97.73%
Market Cap
$3.07M
Gross Margin
0.00%
TTM Avg
-310.04%
3Y Avg
-329.59%
5Y Avg
-274.54%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Paranovus Entertainment Technology Ltd. (PAVS) | $3.28M | 16.54% | -2068.98% | -924.37% | -585.77% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | 79.65% | 78.98% | 76.82% | 80.07% |
| MBody AI Ltd. (MBAI)vs › | $3.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | 0.00% | 0.00% | 25.00% | 50.00% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | 92.09% | 93.19% | 96.59% | 97.73% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | 0.00% | -310.04% | -329.59% | -274.54% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | 34.17% | 21.29% | 6.69% | 5.35% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
16.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | -56.95% |
| 2025-09-30 | 11.27% |
| 2025-03-31 | -6161.27% |
| 2024-09-30 | -264.01% |
| 2024-03-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-03-31 | 0.40% |
| 2022-09-30 | 2.32% |
| 2022-03-31 | -4.61% |
| 2021-09-30 | 12.10% |
| 2021-03-31 | 17.33% |
| 2020-09-30 | 43.78% |
| 2020-03-31 | 43.30% |
| 2019-09-30 | 50.47% |
| 2019-03-31 | 50.46% |
| 2018-09-30 | 50.41% |
| 2018-03-31 | 47.26% |
| 2017-09-30 | 48.27% |
